|Classification and external resources|
A histologic view of an endometrial adenocarcinoma, showing many atypical nuclei.
The most common subtype is endometrioid carcinoma making up more than 80% of all cases. They typically occurs within a few decades of menopause, is associated with obesity, excessive estrogen exposure, and often develops in the setting of endometrial hyperplasia. Approximately 40% are due to obesity. Endometrial cancer may sometimes be referred to as "uterine cancer". However, different cancers may develop not only from the endometrium itself but also from other tissues of the uterus, including cervical cancer, sarcoma of the myometrium, and trophoblastic disease.
A total abdominal hysterectomy (surgical removal of the uterus) with bilateral salpingo-oophorectomy (removal of the fallopian tubes and ovaries on both sides) is the most common treatment. The five year survival rate in the United States is 81.5%. The prognosis is favorable for stage I and II cancer.
Globally as of 2012, endometrial cancers occurred in 320,000 people and caused 76,000 deaths. They are the most common cancers of the female reproductive tract in developed countries. Rates are on a slow rise due to an increasing population age and an increasing body mass index. Endometrial carcinoma is the third most common cause of gynecologic cancer death (behind ovarian and cervical cancer).
- 1 Signs and symptoms
- 2 Risk factors
- 3 Diagnosis
- 3.1 Clinical evaluation
- 3.2 Classification
- 3.3 Metastasis
- 3.4 Histopathology
- 3.5 Staging
- 4 Management
- 5 Prognosis
- 6 Epidemiology
- 7 See also
- 8 References
- 9 External links
Signs and symptoms
Vaginal bleeding and/or spotting in postmenopausal women is a common early sign of endometrial cancer, especially in adenocarcinoma; it is seen in approximately 2/3 of cases. Abnormal menstrual periods or extremely long, heavy, or frequent episodes of bleeding in premenopausal women may also signify endometrial cancer. Thin white or clear vaginal discharge is a symptom in postmenopausal women.
More advanced disease shows more obvious symptoms or findings palpable on a physical exam. The uterus may become enlarged or the cancer may spread, causing lower abdominal pain or pelvic cramping. Pyometra may occur in advanced cases of the disease.
These symptoms are often not indicative of endometrial cancer; it is the cause of these symptoms in 10-15% of women.
Risk factors for endometrial cancer include a history of obesity, diabetes mellitus, or breast cancer, use of tamoxifen (a drug used for estrogen-positive breast cancers), nulliparity (never having carried a pregnancy), late menopause, and high levels of estrogen (including estrogen-producing tumors and estrogen intake). Development of an endometrial hyperplasia (overgrowth of endometrial cells) is a serious risk factor because hyperplasias can and often do develop into adenocarcinoma, though cancer can develop without the presence of a hyperplasia. 8-30% of atypical endometrial hyperplasias develop into cancer within 10 years, whereas 1-3% of non-atypical hyperplasias do so in the same timeframe. An atypical hyperplasia is one with visible abnormalities in the nuclei. Premalignant endometrial hyperplasias are also referred to as endometrial intraepithelial neoplasia.
Most of the risk factors for endometrial cancer involve the endocrine system. Obesity involves an excess of adipose tissue, which converts the hormone intermediate androstenedione into estrone, one of the estrogens. Excess adipose tissue produces higher levels of estrone in the blood, which causes less or no ovulation and exposes the endometrium to continuously high levels of estrogens. Obesity also causes lower levels of sex-hormone sequestration, which also leads to higher levels of circulating estrogen, as well as insulin resistance, which can lead to diabetes mellitus. Other conditions associated with obesity, including gallbladder disease and hypertension, are also associated with endometrial cancer. Polycystic ovary syndrome (PCOS), which also causes irregular or no ovulation, is associated with higher rates of endometrial cancer for the same reasons as obesity.
Other practices that increase the level of circulating estrogen greatly increase the risk for endometrial cancer. Estrogen replacement therapy during menopause when not balanced with progestin, especially in high doses, is one example. There is a correlation between higher doses and/or longer periods of unopposed estrogen and higher risk of endometrial cancer. A longer period of fertility — either from early menarche or late menopause — is also a risk factor. Increasing age is another risk factor.
Therapy for other forms of cancer can also increase the risk of endometrial cancer. Tamoxifen, a drug used to treat estrogen-positive breast cancers, has been associated with endometrial cancer in approximately 0.1% of users, particularly older women, but the benefits for survival from tamoxifen generally outweigh the risk of endometrial cancer. A 1-2 year course of tamoxifen approximately doubles the risk of endometrial cancer, and a 5-year course of therapy quadruples that risk. Previously having ovarian cancer is a risk factor for endometrial cancer, as is having previous radiotherapy. Specifically, ovarian granulosa cell tumors and thecomas are ovarian tumors associated with endometrial cancer.
The environmental risk factors for endometrial cancers are not well characterized, but a high intake of animal fat has been implicated. Immigration studies have shown that there is some environmental component to endometrial cancer.
Genetics can also be implicated in endometrial cancer. Lynch syndrome, an autosomal dominant genetic disorder that causes colorectal cancer, also causes endometrial cancer, especially in premenopausal women. Women with Lynch syndrome have a 40-60% risk of developing endometrial cancer, higher than their risk of developing colorectal cancer. Carcinogenesis in Lynch syndrome comes from a mutation in MLH1 and/or MLH2, genes that participate in the process of mismatch repair. The two genes most commonly associated with gynecological cancer, BRCA1 and BRCA2, are only loosely associated with endometrial cancer; this is likely because breast and ovarian cancers caused by BRCA mutations are often treated with tamoxifen.
Smoking and progestin are both protective against endometrial cancer. Smoking confers a protective effect by altering the metabolism of estrogen and promoting weight loss and early menopause. This protective effect persists long after smoking cessation. Progestin is present in the combined oral contraceptive pill and the hormonal intrauterine device, which reduces risk of endometrial cancer by 30-50% for 10-20 years. Obese women may need higher doses of progestin to obtain the protective effect. Having delivered more than 5 infants (grand multiparity) is also a protective factor.
Routine screening of asymptomatic women is not indicated, since the disease is highly curable in its early stages. Instead, women, particularly menopausal women, should be aware of the symptoms and risk factors of endometrial cancer. A Pap smear is not a useful diagnostic tool for endometrial cancer because the smear will be normal 50% of the time. Results from a pelvic examination are frequently normal, especially in the early stages of disease. Changes in the size, shape or consistency of the uterus and/or its surrounding, supporting structures may exist when the disease is more advanced.
Women with Lynch syndrome should begin to have annual biopsy screening at the age of 35. Some women with Lynch syndrome elect to have a prophylactic hysterectomy and salpingo-oophorectomy to negate the risk of endometrial and ovarian cancer.
Transvaginal ultrasound to evaluate the endometrial thickness in women with postmenopausal bleeding is increasingly being used to evaluate for endometrial cancer. The homogeneity of the tissue visible on transvaginal ultrasound can help to indicate whether the thickness is malignant. Ultrasound findings alone are not conclusive in cases of endometrial cancer, so another screening method (e.g. endometrial biopsy) must be used in conjunction. Other imaging studies are of limited use. CT scans are used for preoperative imaging of tumors that appear advanced on physical exam or have a high-risk subtype. They can also be used to investigate extrapelvic disease. An MRI can be of some use in determining if the cancer has spread to the cervix or if it is an endocervical adenocarcinoma. MRI is also useful for examining the nearby lymph nodes.
Dilation and curettage or an endometrial biopsy are used to obtain a tissue sample for histological examination. Endometrial biopsy is the less invasive option, but it may not give conclusive results every time. Hysteroscopy only shows the gross anatomy of the endometrium, which is often not indicative of cancer, and is therefore not used.
The vast majority of endometrial cancers are carcinomas (usually adenocarcinomas), meaning that they originate from the single layer of epithelial cells that line the endometrium and form the endometrial glands. There are many microscopic subtypes of endometrial carcinoma, but they are broadly organized into two categories, type I and type II, based on clinical features and pathogenesis. The two subtypes are genetically distinct.
Type I endometrial carcinomas occur most commonly in pre- and peri-menopausal women, are more common in white women, often with a history of endometrial hyperplasia. Type I endometrial cancers are often low-grade, minimally invasive into the underlying uterine wall (myometrium), estrogen-dependent, and carry a good prognosis. Type I carcinomas represent 75%-90% of endometrial cancer.
Type II endometrial carcinomas usually occur in older, post-menopausal women, are more common in Black women, and are not associated with increased exposure to estrogen or a history of endometrial hyperplasia. Type II endometrial cancers are often high-grade, with deep invasion into the underlying uterine wall (myometrium), and are of the serous or clear cell type, and carry a poorer prognosis. They can appear to be epithelial ovarian cancer on evaluation of symptoms. They tend to present later than Type I tumors and are more aggressive, with a greater risk of relapse or metastasis.
In endometrioid adenocarcinoma, the cancer cells grow in patterns reminiscent of normal endometrium, with many new glands formed from columnar epithelium with some abnormal nuclei. Low-grade endometrioid adenocarcinomas have well differentiated cells, have not invaded the myometrium, and are seen alongside endometrial hyperplasia. The tumor's glands form very close together, without the stroma tissue that normally separates them. Higher-grade endometrioid adenocarcinomas have less well-differentiated cells, have more solid sheets of tumor cells no longer organized into glands, and are associated with an atrophied endometrium. There are several subtypes of endometrioid adenocarcinoma with similar prognoses, including villoglandular, secretory, and ciliated cell variants. There is also a subtype characterized by squamous differentiation. Some endometrioid adenocarcinomas have foci of mucinous carcinoma.
The genetic mutations most commonly associated with endometrioid adenocarcinoma are in the genes PTEN, a tumor suppressor; PIK3CA, a kinase; KRAS, a GTPase that functions in signal transduction; and CTNNB1, involved in adhesion and cell signaling. The CTNNB1 (beta-catenin) mutation is most commonly mutated in the squamous subtype of endometrioid adenocarcinoma.
Serous carcinoma is a type II endometrial tumor that makes up 5-10% of diagnosed endometrial cancer and is common in postmenopausal women with atrophied endometrium. Serous endometrial carcinoma is aggressive and often invades the myometrium and metastasizes within the peritoneum (seen as omental caking) or the lymphatic system. Histologically, it appears with many atypical nuclei, papillary structures, and, in contrast to endometrioid adenocarcinomas, rounded cells instead of columnar cells. 30% of endometrial serous carcinomas also have psammoma bodies.
Clear cell carcinoma
Clear cell carcinoma is a type II endometrial tumor that makes up less than 5% of diagnosed endometrial cancer. Like serous cell carcinoma, it is usually aggressive and carries a poor prognosis. Histologically, it is characterized by the features common to all clear cells: the eponymous clear cytoplasm when H&E stained and visible, distinct cell membranes. The p53 cell signaling system is not active in endometrial clear cell carcinoma.
Mucinous carcinomas are a rare form of endometrial cancer, making up less than 1-2% of all diagnosed endometrial cancer. Mucinous endometrial carcinomas are most often stage I and grade I, giving them a good prognosis. They typically have well-differentiated columnar cells organized into glands with the characteristic mucin in the cytoplasm. Mucinous carcinomas must be differentiated from cervical adenocarcinoma.
Mixed or undifferentiated carcinoma
Mixed carcinomas are those that have both type I and type II cells, with one making up at least 10% of the tumor. These include the malignant mixed Müllerian tumor, which derives from endometrial epithelium and has a poor prognosis.
Undifferentiated endometrial carcinomas make up less than 1-2% of diagnosed endometrial cancers. They have a worse prognosis than grade III tumors. Histologically, these tumors show sheets of identical epithelial cells with no identifiable pattern.
Endometrial cancer frequently metastasizes to the ovaries and Fallopian tubes when the cancer is located in the upper part of the uterus, and the cervix when the cancer is in the lower part of the uterus. The cancer usually first spreads into the myometrium and the serosa, then into other reproductive and pelvic structures. When the lymphatic system is involved, the pelvic and para-aortal nodes are usually first to become involved, but in no specific pattern, unlike cervical cancer. More distant metastases are spread by the blood and often occur in the lung, as well as the liver, brain, and bone.
There is a three-tiered system for histologically classifying endometrial cancers, ranging from cancers with well-differentiated cells (grade I), to very poorly-differentiated cells (grade III). Grade I cancers are the least aggressive and have the best prognosis, while grade III tumors are the most aggressive and likely to recur. Grade II cancers are intermediate between grades I and III in terms of cell differentiation and aggressiveness of disease.
The histopathology of endometrial cancers is highly diverse. The most common finding is a well-differentiated endometrioid adenocarcinoma, which is composed of numerous, small, crowded glands with varying degrees of nuclear atypia, mitotic activity, and stratification. This often appears on a background of endometrial hyperplasia. Frank adenocarcinoma may be distinguished from atypical hyperplasia by the finding of clear stromal invasion, or "back-to-back" glands which represent nondestructive replacement of the endometrial stroma by the cancer. With progression of the disease, the myometrium is infiltrated.
Endometrioid endometrial adenocarcinoma — intermediate magnification. H&E stain.
Uterine papillary serous carcinoma. H&E stain.
- IA: Tumor is confined to the uterus with less than half myometrial invasion
- IB: Tumor is confined to the uterus with more than half myometrial invasion
- II: Tumor involves the uterus and the cervical stroma
- IIIA: Tumor invades serosa or adnexa
- IIIB: Vaginal and/or parametrial involvement
- IIIC1: Pelvic lymph node involvement
- IIIC2: Para-aortic lymph node involvement, with or without pelvic node involvement
- IVA: Tumor invades bladder mucosa and/or bowel mucosa
- IVB: Distant metastases including abdominal metastases and/or inguinal lymph nodes
Myometrial invasion and involvement of the pelvic and para-aortic lymph nodes are the most commonly seen patterns of spread.
The primary treatment is surgical. Surgical treatment typically consists of hysterectomy including a salpingo-oophorectomy, which is the removal of the uterus, ovaries, and Fallopian tubes. Lymphadenectomy, or removal of pelvic and para-aortic lymph nodes, is performed for tumors of grade II or above. In stage III and IV cancers, cytoreductive surgery is the norm, and a biopsy of the omentum may also be included. Laparotomy, an open-abdomen procedure, is the traditional surgical protocol; however, laparoscopy (keyhole surgery) is associated with lower operative morbidity. The two procedures have no difference in overall survival. 90% of women are treated with some form of surgery. Abdominal hysterectomy is recommended over vaginal hysterectomy because it affords the opportunity to examine and obtain washings of the abdominal cavity to detect any further evidence of cancer. Staging of the cancer is done during the surgery.
Surgery is almost always the primary option for treatment of endometrial cancer. The few contraindications include inoperable tumor, massive obesity, a particularly high-risk operation, or a desire to preserve fertility. Women who wish to preserve their fertility and have stage I cancer can be treated with progestins, with or without concurrent tamoxifen therapy. This therapy can be continued until the cancer does not respond to treatment or until childbearing is done.
Surgery can be combined with radiation therapy and chemotherapy in cases of high-risk or high-grade cancers. In cases where surgery is not indicated, palliative chemotherapy is an option; higher-dose chemotherapy is associated with longer survival. Adjuvant chemotherapy is a recent innovation, consisting of some combination of paclitaxel (or other taxanes), doxorubicin, and platins (particularly cisplatin). Adjuvant chemotherapy has been found to increase survival in stage III and IV cancer more than adjuvant radiotherapy.
Adjuvant radiotherapy is commonly used in early-stage endometrial cancer. It can be delivered through vaginal brachytherapy (VBT), which is becoming the preferred route due to its reduced toxicity, or external beam radiotherapy (EBRT). VBT is used to treat any remaining cancer solely in the vagina, whereas EBRT can be used to treat remaining cancer elsewhere in the pelvis following surgery. However, the benefits of adjuvant radiotherapy are controversial. Though EBRT significantly reduces the rate of relapse in the pelvis, overall survival and metastasis rates are not improved.
Women with endometrial cancer should not have routine surveillance imaging to monitor the cancer unless new symptoms appear or tumor markers begin rising. Imaging without these indications is discouraged because it is unlikely to detect a recurrence or improve survival, and because it has its own costs and side effects.
Complications of treatment
Adjuvant radiotherapy for endometrial cancer can be delivered either through external beam radiotherapy or vaginal brachytherapy. Both are associated with side effects, particularly in the GI tract.
The tumor marker CA-125 is frequently found to be elevated in endometrial cancer and can be used to monitor response to treatment, particularly in serous cell cancer or advanced disease. Periodic MRIs or CT scans may be necessary in women with advanced disease; all women with a history of endometrial cancer should receive more frequent pelvic examinations for the 5 years following treatment.
While endometrial cancers are 40% more common in Caucasian women, an African American woman who is diagnosed with uterine cancer is twice as likely to die (possibly due to the higher frequency of aggressive subtypes in that population, but more probably due to delay in the diagnosis). Approximately 8,000 people die annually from endometrial cancer in the United States.
|Stage||5 year survival rate|
The 5-year survival rate for endometrial adenocarcinoma following appropriate treatment is 80%. Most women, over 70%, have FIGO stage I cancer, which has the best prognosis. Stage III and IV cancer has a worse prognosis, but is relatively rare, occurring in only 13% of cases. Older age indicates a worse prognosis. The median survival time for stage III-IV endometrial cancer is 9-10 months.
Recurrence of early stage endometrial cancer ranges from 3 to 17%, depending on primary and adjuvant treatment. Most recurrences (70%) occur in the first three years.
Higher-staged cancers are more likely to recur — those that have invaded the myometrium or cervix, or that have metastasized into the lymphatic system, are particularly likely to recur. Papillary serous carcinoma, clear cell carcinoma, and endometrioid carcinoma are the subtypes at the highest risk of recurrence. High-grade histological subtypes are also at elevated risk for recurrence.
The most common site of recurrence is in the vagina; vaginal relapses of endometrial cancer have the best prognosis. If relapse occurs from a cancer that has not been treated with radiation, EBRT is the first-line treatment and is often successful. If a cancer treated with radiation occurs, pelvic exenteration is the only option for curative treatment. Palliative chemotherapy, cytoreductive surgery, and radiation are also performed.
Quality of life
Over 70% of endometrial cancer survivors have a other health problems and on average they have between 2 and 3 of these. It has been shown that obesity has a negative consequence for the quality of life of endometrial cancer survivors.
On average endometrial cancer survivors make more use of healthcare check ups than other people. This seems to be related to fear for recurrence, and it has been shown that this fear does not decrease even after a period of 10 years.
Studies among endometrial cancer survivors show that satisfaction with information provided about the disease and treatment increases the quality of life, lowers depression and results in less anxiety. People who receive information on paper, compared to oral, indicate that they receive more information and are more satisfied about the information provided. The American Institute of Medicine and the Dutch Health Council recommend the use of a Survivorship Care Plan; which is a summary of patients' course of treatment, with recommendations for subsequent surveillance, management of late effects, and strategies for health promotion.
Endometrial cancer is the most frequently diagnosed gynecologic cancer and the fourth most prevalent cancer overall in the United States. It has an incidence of 12.9 cases per 100,000 women annually in developed countries. Worldwide, approximately 320,000 women are diagnosed with endometrial cancer each year, making it the fifth most prevalent cancer in women. It is more common in developed countries; the risk of endometrial cancer is 1.6% compared to 0.6% in developing countries. Unlike most cancers, the incidence rate has risen dramatically in recent years, including an increase of over 40% in the United Kingdom between 1993 and 2013. Some of this rise may be due to the increase in obesity rates in developed countries, increasing life expectancies, and lower birth rates.
It appears most frequently during perimenopause and menopause, between the ages of 50 and 65; overall, 75% of endometrial cancer occurs after menopause. However, 5% of cases occur in women younger than 40 and 10-15% occur in women under 50 years of age. This age group is at risk for developing ovarian cancer at the same time. Less than 5% of cases are associated with Lynch syndrome.
Endometrial adenocarcinoma is the most common endometrial cancer, accounting for over 90% of cases. It was diagnosed in approximately 280,000 women in the world in 2008, and killed 33,000 in developed countries that year.
- World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 6.7. ISBN 9283204298.
- "SEER Stat Fact Sheets: Endometrial Cancer". NCI. Retrieved 18 June 2014.
- World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.12. ISBN 9283204298.
- Kong, Anthony; Johnson, Nick; Kitchener3, Henry C; Lawrie, Theresa A (18 April 2012). "Adjuvant radiotherapy for stage I endometrial cancer". Cochrane Gynaecological Cancer Group (John Wiley & Sons, Ltd.). doi:10.1002/14651858.CD003916.pub4.
- Hoffman, Barbara L. (2012). Williams Gynecology: Chapter 33, Endometrial Cancer (2nd ed.). New York: McGraw-Hill Medical. ISBN 978-0071716727.
- Saso, S.; Chatterjee, J.; Georgiou, E.; Ditri, A. M.; Smith, J. R.; Ghaem-Maghami, S. (6 July 2011). "Endometrial cancer". BMJ 343 (jul06 2): d3954–d3954. doi:10.1136/bmj.d3954.
- Galaal, Khadra; Al Moundhri, Mansour; Bryant, Andrew; Lopes, Alberto D.; Lawrie, Theresa A. (15 May 2014). "Adjuvant chemotherapy for advanced endometrial cancer". The Cochrane Collaboration (John Wiley and Sons, Ltd.). doi:10.1002/14651858.CD010681.pub2.
- Soliman, Pamela T.; Lu, Karen H. (2013). "Neoplastic Diseases of the Uterus". Comprehensive Gynecology (6th ed.). ISBN 978-0-323-06986-1.
- Luo, Li; Luo, Bing; Zheng, Ying; Zhang, Heng; Li, Jing; Sidell, Neil (5 June 2013). Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia. Cochrane Menstrual Disorders and Subfertility Group. doi:10.1002/14651858.CD009458.pub2.
- Vale, Claire L; Tierney, Jayne; Bull, Sarah J; Symonds, Paul R (15 August 2012). "Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma". The Cochrane Collaboration (John Wiley and Sons, Ltd.). doi:10.1002/14651858.CD003915.pub4.
- Staley, Helen; McCallum, Iain; Bruce, Julie (17 October 2012). Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Breast Cancer Group. doi:10.1002/14651858.CD007847.pub2. "There is evidence from other reports that tamoxifen increases the risk of endometrial cancer although the data presented in this review describes only 10 events occurring in 1798 participants (0.5%) after seven years of follow-up."
- Coleman, Robert L.; Ramirez, Pedro T.; Gershenson, David M. (2013). "Neoplastic Diseases of the Ovary". Comprehensive Gynecology (6th ed.). ISBN 978-0-323-06986-1.
- Colombo, N.; Preti, E.; Landoni, F.; Carinelli, S.; Colombo, A.; Marini, C.; Sessa, C. (9 September 2011). "Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology 22 (Supplement 6): vi35–vi39. doi:10.1093/annonc/mdr374.
- Johnson, Nick; Bryant, Andrew; Miles, Tracie; Hogberg, Thomas; Cornes, Paul (5 October 2011). "Adjuvant chemotherapy for endometrial cancer after hysterectomy". Cochrane Gynaecological Cancer Group. doi:10.1002/14651858.CD003175.pub2.
- Richard Cote, Saul Suster, Lawrence Weiss, Noel Weidner (Editor) (2002). Modern Surgical Pathology (2 Volume Set). London: W B Saunders. ISBN 0-7216-7253-1.
- Johnson, Nick; Bryant, Andrew; Miles, Tracie; Hogberg, Thomas; Cornes, Paul (5 October 2011). Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Gynaecological Cancer Group. doi:10.1002/14651858.CD003175.pub2.
- "Stage Information for Endometrial Cancer". National Cancer Institute. 23 April 2014.
- Galaal, Khadra; Bryant, Andrew (12 September 2012). Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Gynaecological Cancer Group. doi:10.1002/14651858.CD006655.pub2.
- Society of Gynecologic Oncology (February 2014), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (Society of Gynecologic Oncology), retrieved 19 February 2013, which cites
- Sartori, E.; Pasinetti, B.; Carrara, L.; Gambino, A.; Odicino, F.; Pecorelli, S. (October 2007). "Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients". Gynecologic Oncology 107 (1): S241–S247. doi:10.1016/j.ygyno.2007.07.025.
- Berchuck, A (October 1995). "Postsurgical Surveillance of Patients with FIGO Stage I/II Endometrial Adenocarcinoma". Gynecologic Oncology 59 (1): 20–24. doi:10.1006/gyno.1995.1262.
- American Cancer Society (2 March 2014). "Survival by stage of endometrial cancer". Retrieved 10 June 2014.
- Nicolaije, K.A. et al. (May 2013). "Follow-up practice in endometrial cancer and the association with patient and hospital characteristics: A study from the population-based PROFILES registry". Gynecologic Oncology 129 (2): 324–331. PMID 23435365.
- Ang, Christine; Bryant, Andrew; Barton, Desmond P.J.; Pomel, Christophe; Naik, Raj (4 February 2014). Exenterative surgery for recurrent gynaecological malignancies. Cochrane Gynaecological Cancer Group. doi:10.1002/14651858.CD010449.pub2.
- Oldenburg C.S. et al. The relationship of body mass index with quality of life among endometrial cancer survivors: a study from the population-based PROFILES registry. Gynecologic Oncology, 129 (1), April 2013, page 216–21, PMID 23296262.
- Ezendam N.P. et al. Health Care Use Among Endometrial Cancer Survivors: A Study From PROFILES, a Population-Based Survivorship Registry. International Journal of Gynecological Cancer, Epub ahead of print, July 22, 2013, PMID 23881102.
- Husson O. et al, The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review, Ann Oncol, 22, 2011, page 761–772
- Nicolaije K.A. et al. Endometrial cancer survivors are unsatisfied with received information about diagnosis, treatment and follow-up: A study from the population-based PROFILES registry, Patient education and counseling, 88(3), Sep 2012, page 427–35, PMID 22658248
- Van de Poll-Franse L.V. et al. The impact of a cancer Survivorship Care Plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials, 5 (12). 2011 Dec, page 256, PMID 22141750
- American Cancer Society's Detailed Guide: Endometrial Cancer
- U.S. National Cancer Institute: Endometrial cancer
- NIH Endometrial cancer fact page
- Anatomical pathology images
- MedPix endometrial cancer images